Clinical Trial Update: Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients [Phase 2]

View source ↗

Summary

Phase 2 dose-finding study evaluating reversal of deep rocuronium-induced neuromuscular block with sugammadex in morbidly obese patients has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Morbid Obesity

Drugs mentioned

• Rocuronium (rocuronium bromide)
• Sugammadex (sugammadex)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Morbidly Obese Patients | Phase 2 | Status: COMPLETED